Eli Lilly and Company Q2 Earnings Call Highlights

Lilly reported 48% year-over-year revenue growth in Q2 2026, with MOUNJARO and ZEPBOUND generating $14.9 billion in combined sales. The company raised its full-year revenue outlook to $85 billion–$87 billion and adjusted earnings-per-share guidance to $35.50–$36.50. Demand for obesity medicines remained strong, with U.S. obesity prescriptions up 78% year over year. Lilly said the Medicare GLP-1 Bridge Program expanded coverage for its obesity medicines by 35%, while Foundayo’s launch continued gaining prescribers and international approvals. Lilly reported positive Phase III results for experimental medicine retatrutide and plans to seek U.S. approval in the first quarter of 2027. The company also expanded its pipeline through acquisitions in infectious disease, mental health and neuroscience, while investing in new manufacturing facilities. Eli Lilly and Company NYSE: LLY reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered growth across key products and major geographies, advanced its pipeline and added assets through business development. Lilly said its key products increased by nearly $6.8 billion during the quarter, while its oncology, immunology and neuroscience medicines collectively grew 121% from the prior-year period. “We delivered strong business results, received regulatory approval for new indications, shared positive phase III trial results, added new medicines to our pipeline, and expanded access to medicines for patients,” Ricks said. Chief Financial Officer Lucas Montarce said second-quarter revenue rose 48% from the same period in 2025. MOUNJARO and ZEPBOUND combined for $14.9 billion in revenue, contributing $6.3 billion of year-over-year growth. Non-GAAP earnings per share were $8.38, compared with $6.31 in the prior-year quarter. The second-quarter figure included $3.03 in acquired in-process research and development charges. Lilly’s non-GAAP performance margin was 54.8%, up 9 percentage points from a year earlier, while gross margin reached 86.3%. U.S. revenue increased 33%, primarily on volume growth for ZEPBOUND and MOUNJARO as well as contributions from the company’s immunology, oncology and neuroscience portfolio. U.S. price declined 3%; excluding changes to estimates for rebates and discounts, price declined 9%, Montarce said. Outside the U.S., revenue rose 55% in constant currency in Europe, aided by MOUNJARO volume growth and a $250 million Jardiance milestone payment. Revenue grew 30% in Japan, 93% in China and 136% in the rest of the world on a constant-currency basis, with MOUNJARO a principal driver. Lilly raised its full-year 2026 revenue outlook to $85 billion to $87 billion, increasing the low end by $3 billion and the high end by $2 billion. It now expects a non-GAAP performance margin of 49% to 50.5% and non-GAAP earnings per share of $35.50 to $36.50. Montarce said the guidance incorporates certain factors that could affect quarterly comparisons, including prior-period adjustments to U.S. rebate and discount estimates, European vacation-related seasonality in the third quarter, and fourth-quarter seasonality in the U.S. Type 2 diabetes market. Lilly said the...